Navigation Links
Gene variant identified as a heart disease risk factor for women
Date:7/22/2014

When it comes to heart disease, Dr. Ross Feldman says women are often in the dark. Historically, it was thought that heart disease was a men's-only disease, however, data has shown that post-menopausal women are just as likely as men to get heart disease and are less likely to be adequately diagnosed and treated. New research from Western University published online this week in the British Journal of Clinical Pharmacology brings to light a genetic basis for heart disease in women and helps to identify which women are more prone to heart disease.

The study, led by Dr. Feldman, a clinical pharmacologist at London Health Sciences Centre and a researcher at the Schulich School of Medicine & Dentistry's Robarts Research Institute, identifies a common gene variant in women for the G-protein coupled estrogen receptor 30 (GPER) that makes them significantly more likely to have high blood pressure, the single biggest risk factor for heart attack and stroke.

GPER, when functioning normally, is activated in part by the hormone estrogen and has been previously shown to relax the blood vessels, and in turn, lower blood pressure. This new study demonstrates that many women have a less functional form of GPER, increasing their risk of developing high blood pressure.

The research looked at the effect of expression of the GPER gene variant versus the normal GPER gene in the vascular smooth muscle cells as well as its association with blood pressure in humans. It also looked at the frequency of the gene variant in a group of women referred a tertiary care clinic at London Health Sciences Centre. The study found that women, but not men, carrying the GPER gene variant had higher blood pressure, and almost half of women who attended a hard-to-treat blood pressure clinic, where Dr. Feldman is a physician, expressed the variant. Twice as many women than men with hard to treat hypertension carried the gene.

"This is one step in understanding
'/>"/>

Contact: Crystal Mackay
crystal.mackay@schulich.uwo.ca
519-661-2111 x80387
University of Western Ontario
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Common gene variants account for most of the genetic risk for autism
2. Splice variants reveal connections among autism genes
3. Certain genetic variants may identify patients at higher risk of bladder cancer recurrence
4. Gene variants protect against relapse after treatment for hepatitis C
5. Researchers identify genomic variant associated with sun sensitivity, freckles
6. Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers
7. Noodles Box launches variants in serving size
8. Gene variant ID could lead to better fatty liver disease diagnosis
9. Common gene variants explain 42 percent of antidepressant response
10. An international study identifies new DNA variants that increase the risk for cancer
11. eVariant Welcomes Advocate Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 My Clients Plus ( http://www.MyClientsPlus.com ... The new module enables easy administration and routing ... quality care. , This application allows users such as ... attach a to-do item to a specific client, categorize ... up reoccurring reminders for follow-ups. It's designed to ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update ... FDA on Sit and Slim II . , ... or use Sit and Slim II because it contains ... as weight loss product on various websites and possibly in ... 2010 for safety reasons, can significantly increase blood pressure and/or ...
(Date:10/20/2014)... OH (PRWEB) October 20, 2014 ... Assisted Living Center on Oct. 14. The $11 million ... and services, and a cooked-to-order kitchen with full-service restaurant ... Akron’s premier choice for first class Assisted Living apartments,” ... “Our residents deserve the highest quality of care and ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... California (PRWEB) October 20, 2014 Final Cut ... the release of the Citrus theme for FCPX filmmakers ... would use to describe the Citrus theme” Says Christina Austin, ... easy to look so professional.” , Citrus comes with all ... with the template are: four transitions for added style, a ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2
... vaccine that wards off infections , , THURSDAY, March 6 ... found on streptococcus bacteria may provide protection against strep ... by University of California, San Diego (UCSD), researchers developed ... streptococcal M protein, which plays a critical role in ...
... N.J., March 6 Smart Balance Inc. (Nasdaq:,SMBL) ... http://www.smartbalance.com on,March 14, 2008, at 9:30 a.m. ... will be issued at approximately 7 a.m. EDT ... mode. The webcast is also,available through the following ...
... those ... services - Immediate Termination of Endoscopy Center of Nevada clinics ... - Online information Available to Public, LAS VEGAS, March 6 Anthem ... Blue Shield,Foundation will make a $50,000 grant to the Nevada Health Centers to go,toward ...
... Trubion Pharmaceuticals,Inc. (Nasdaq: TRBN ), today announced that it ... ended Dec. 31, 2007, after the,close of market on March ... 13, 2008, at 2 p.m. PDT (5 p.m. EDT)., ... EDT, March,13, 2008, Participants are invited to call 877-545-1491 ...
... Calif., March 6 Longs Drug,Stores Corporation (NYSE: LDG ) today reported preliminary total retail drug,store sales ... in the comparable period,a year ago., , (Dollars in millions) ... retail drug store sales ... ...
... Inc. (Nasdaq: IDIX ), a biopharmaceutical company ... the treatment of human viral,and other infectious diseases, ... and year ended December 31, 2007. At December ... totaled,$112.0 million., Significant company ...
Cached Medicine News:Health News:Scientists Engineer Protein That Could Battle Strep 2Health News:Smart Balance to Host Webcast/Conference Call on 2007 Fourth-Quarter and Full-Year Results 2Health News:Anthem Blue Cross and Blue Shield Acts to Support Las Vegans Impacted by Endoscopy Center Practices 2Health News:Anthem Blue Cross and Blue Shield Acts to Support Las Vegans Impacted by Endoscopy Center Practices 3Health News:Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call 2Health News:Longs Reports Preliminary February Retail Drug Store Sales 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 2Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 3Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 4Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 5Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 6Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 7Health News:Idenix Pharmaceuticals Reports Fourth Quarter and Year-End 2007 Financial Results 8
(Date:10/20/2014)... SAN DIEGO , Oct. 20, 2014   BioNano ... the Irys system: the ability to collect human data at ... on a single chip.  This new capability was established and ... for the Irys TM System and will ... next two months. BioNano will be showcasing this advancement at ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs announces ... in Albany, NY for admixing, ... company meets and/or exceeds the FDA standards for safety ... CFR Part 211. The 10,000 square ... levels of quality assurance and quality control. The company ...
(Date:10/19/2014)... , October 20, 2014 Shire plc ... Bowling , Interim Chief Financial Officer (CFO), has notified the Board ... role to pursue a new career opportunity as CFO of Severn ... 2015 and the company will commence a search for a new ... "James has helped build and lead a high-quality finance ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4
... Ill., Nov. 8, 2010 ... ... --> ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var r ...
... 8, 2010 Reportlinker.com announces that a ... its catalogue: The Future ... leading companies, and opportunities for target expansion ... G-Protein-coupled receptors (GPCRs) constitute the largest ...
Cached Medicine Technology:Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 2Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 3Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 4Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 5Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 6Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 7Abbott Joins Clinton Health Access Initiative in Effort to Improve Infant Testing for HIV in Africa 8The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 2The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 3The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 4The Future of GPCRs in Drug Discovery: Novel Technologies, Leading Companies, and Opportunities for Target Expansion 5